Silo Pharma (SILO) said Wednesday the US Patent and Trademark Office issued a notification for its "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females" application.
The patent reinforces protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder, the company said.
"This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15," said Chief Executive Officer Eric Weisblum.
Price: 1.36, Change: -0.03, Percent Change: -2.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。